V-set and immunoglobulin domain containing 4 (VSIG4) emerges as a significant player in the immune system pathways. It has been previously identified as a potential hub gene for Alzheimer's disease (AD) and aging, underscoring its importance in understanding these conditions.
Objective
This study aimed to evaluate the diagnostic potential of serum VSIG4 and identify trends in serum VSIG4 in relationship with other biomarkers and neurological tests.
Methods
ELISA was used to measure the serum concentration of VSIG4 in AD, compared to healthy subjects. The relationship between VSIG4 levels and the age of the subjects, as well as other AD-related serum proteins and various measures of cognition was examined.
Results
VSIG4 was significantly elevated in the serum of AD patients compared to healthy controls (p = 0.0074). Significant correlations were identified between serum VSIG4 and other notable proteins related to AD and inflammation, such as total tau, neurofilament light (NfL), YKL-40, CD14, FABP3, and TNF-α. Significant correlations were also identified between VSIG4 concentration and the results of neurological tests.
Conclusions
Serum VSIG4 may reflect neuroinflammation and altered lipid processing, affecting the cognitive performance of AD and aging.
LaRoccaTJCavalierANRobertsCM, et al.Amyloid beta acts synergistically as a pro-inflammatory cytokine. Neurobiol Dis2021; 159: 105493.
2.
OberlinLEEricksonKIMackeyR, et al.Peripheral inflammatory biomarkers predict the deposition and progression of amyloid-beta in cognitively unimpaired older adults. Brain Behav Immun2021; 95: 178–189.
3.
KinneyJWBemillerSMMurtishawAS, et al.Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y)2018; 4: 575–590.
4.
WalkerKAFicekBNWestbrookR. Understanding the role of systemic inflammation in Alzheimer's disease. ACS Chem Neurosci2019; 10: 3340–3342.
5.
NovoaCSalazarPCisternasP, et al.Inflammation context in Alzheimer's disease, a relationship intricate to define. Biol Res2022; 55: 39.
6.
XieJVan HoeckeLVandenbrouckeRE. The impact of systemic inflammation on Alzheimer's disease pathology. Front Immunol2021; 12: 796867.
7.
NationDASweeneyMDMontagneA, et al.Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med2019; 25: 270–276.
8.
WeaverDF. Amyloid-beta is a cytokine. Alzheimers Dement2023; 19: 4237–4247.
9.
WeaverDF. Amyloid beta is an early responder cytokine and immunopeptide of the innate immune system. Alzheimers Dement (N Y)2020; 6: e12100.
10.
HuangWJZhangXChenWW. Role of oxidative stress in Alzheimer's disease. Biomed Rep2016; 4: 519–522.
11.
SepeFNChiasseriniDParnettiL. Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies. Futur Neurol2018; 13: 199–207.
12.
YinF. Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise. FEBS J2023; 290: 1420–1453.
13.
YangRKongWLiuK, et al.Exploring imaging genetic markers of Alzheimer's disease based on a novel nonlinear correlation analysis algorithm. J Mol Neurosci2024; 74: 35.
14.
OuGYLinWWZhaoWJ. Construction of long noncoding RNA-associated ceRNA networks reveals potential biomarkers in Alzheimer's disease. J Alzheimers Dis2021; 82: 169–183.
15.
XuJZhouHXiangG. Identification of key biomarkers and pathways for maintaining cognitively normal brain aging based on integrated bioinformatics analysis. Front Aging Neurosci2022; 14: 833402.
16.
LiJDiaoBGuoS, et al.VSIG4 Inhibits proinflammatory macrophage activation by reprogramming mitochondrial pyruvate metabolism. Nat Commun2017; 8: 1322.
17.
HelmyKYKatschkeKJJrGorganiNN, et al.CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell2006; 124: 915–927.
18.
JiNWuLShiH, et al.VSIG4 Attenuates NLRP3 and ameliorates neuroinflammation via JAK2-STAT3-A20 pathway after intracerebral hemorrhage in mice. Neurotox Res2022; 40: 78–88.
19.
LyuQPangXZhangZ, et al.Microglial V-set and immunoglobulin domain-containing 4 protects against ischemic stroke in mice by suppressing TLR4-regulated inflammatory response. Biochem Biophys Res Commun2020; 522: 560–567.
20.
CaiPWangJXuJ, et al.V-set and immunoglobulin domain containing 4 inhibits oxidative stress, mitochondrial dysfunction, and inflammation to attenuate Parkinson's disease progression by activating the JAK2/STAT3 pathway. J Neuroimmunol2024; 391: 578345.
21.
WangKXieMZhuL, et al.Ciliary neurotrophic factor protects SH-SY5Y neuroblastoma cells against Abeta1–42-induced neurotoxicity via activating the JAK2/STAT3 axis. Folia Neuropathol2015; 53: 226–235.
22.
ChibaTYamadaMAisoS. Targeting the JAK2/STAT3 axis in Alzheimer's disease. Expert Opin Ther Targets2009; 13: 1155–1167.
23.
O'BryantSEEdwardsMJohnsonL, et al.Texas Mexican American adult normative studies: normative data for commonly used clinical neuropsychological measures for English- and Spanish-speakers. Dev Neuropsychol2018; 43: 1–26.
24.
O'BryantSEListaSRissmanRA, et al.Comparing biological markers of Alzheimer's disease across blood fraction and platforms: comparing apples to oranges. Alzheimers Dement (Amst)2016; 3: 27–34.
25.
GonzalesMMWangCPShortMI, et al.Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort. Alzheimers Dement (Amst)2022; 14: e12298.
26.
HallBMGleibermanASStromE, et al.Immune checkpoint protein VSIG4 as a biomarker of aging in murine adipose tissue. Aging Cell2020; 19: e13219.
27.
PandaSPKesharwaniADattaS, et al.JAK2/STAT3 As a new potential target to manage neurodegenerative diseases: an interactive review. Eur J Pharmacol2024; 970: 176490.
28.
LinALZhengWHalloranJJ, et al.Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease. J Cereb Blood Flow Metab2013; 33: 1412–1421.
29.
LeeDJWHodzic KuerecAMaierAB. Targeting ageing with rapamycin and its derivatives in humans: a systematic review. Lancet Healthy Longev2024; 5: e152–e162.
30.
OizumiHYamasakiKSuzukiH, et al.Fatty acid-binding protein 3 expression in the brain and skin in human synucleinopathies. Front Aging Neurosci2021; 13: 648982.
31.
ClarkALHaleyAPDuarteA, et al.Fatty acid-binding protein 3 is a marker of neurodegeneration and white matter hyperintensity burden in Mexican American older adults. J Alzheimers Dis2022; 90: 61–68.
32.
NamELeeYBMoonC, et al.Serum tau proteins as potential biomarkers for the assessment of Alzheimer's disease progression. Int J Mol Sci2020; 21: 5007.
33.
CoppensSLehmannSHopleyC, et al.Neurofilament-light, a promising biomarker: analytical, metrological and clinical challenges. Int J Mol Sci2023; 24: 11624.
34.
ChatterjeePPedriniSDoeckeJD, et al.Plasma Abeta42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement2023; 19: 1117–1134.
35.
RosenCMattssonNJohanssonPM, et al.Discriminatory analysis of biochip-derived protein patterns in CSF and plasma in neurodegenerative diseases. Front Aging Neurosci2011; 3: 1.
36.
RasmussenKLNordestgaardBGFrikke-SchmidtR, et al.An updated Alzheimer hypothesis: complement C3 and risk of Alzheimer's disease-A cohort study of 95,442 individuals. Alzheimers Dement2018; 14: 1589–1601.
37.
GedamMZhengH. Complement C3aR signaling: immune and metabolic modulation and its impact on Alzheimer's disease. Eur J Immunol2024; 54: e2350815.
38.
MichaudMBalardyLMoulisG, et al.Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc2013; 14: 877–882.
39.
LicastroFPedriniSCaputoL, et al.Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?J Neuroimmunol2000; 103: 97–102.
40.
LlorensFThuneKTahirW, et al.YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener2017; 12: 83.
41.
WechslerD. WMS-R: Wechsler memory scale–revised: manual. San Antonio: Psychological Corp.: Harcourt Brace Jovanovich, 1987, p.viii, 150 p.
42.
WechslerD. The psychometric tradition – developing the Wechsler adult intelligence scale. Contemp Educ Psychol1981; 6: 82–85.
43.
TulskyDS. A new look at the WMS-III: new research to guide clinical practice. J Clin Exp Neuropsychol2004; 26: 453–458.
44.
HaalandKYPriceLLarueA. What does the WMS-III tell us about memory changes with normal aging?J Int Neuropsychol Soc2003; 9: 89–96.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
